论文部分内容阅读
目的观察苦参碱注射液联合化疗对急性髓系白血病中miR-125b表达的影响。方法选择2013年3月至2015年2月本院收治的76例急性髓系白血病患者,依据随机数表法分为试验组和对照组,每组各38例。对照组患者采取红霉素+阿糖胞苷化疗方案进行治疗,试验组患者在此基础上联合使用苦参碱注射液20 m L,所有患者的疗程均为2周。比较2组患者治疗前后Karnofsky评分、miR-125的表达水平变化,观察2组患者的临床疗效及不良反应。结果治疗后,试验组患者的总有效率(86.84%)比对照组(60.53%)明显增高(P<0.05)。试验组患者的Karnofsky评分(83.23±14.35)也明显高于对照组(77.22±11.31)(P<0.05)。试验组患者的miR-125b表达(5.02±0.75)明显低于对照组(11.42±1.44)(P<0.05)。试验组患者出现的Ⅲ-Ⅳ白细胞降低率(2.63%)、红细胞降低率(2.63%)、血小板减少率(0)、肝功能损伤率(2.63%)、口腔黏膜炎及胃肠道严重不良反应率均明显低于对照组(P<0.05)。结论苦参碱注射液联合化疗能降低miR-125b在急性髓系白血病患者中的表达。
Objective To observe the effect of matrine injection combined with chemotherapy on the expression of miR-125b in acute myeloid leukemia. Methods From March 2013 to February 2015, 76 patients with acute myeloid leukemia admitted to our hospital were divided into experimental group and control group according to the random number table method, with 38 cases in each group. Patients in the control group taking erythromycin + cytarabine chemotherapy treatment, patients in the test group used in conjunction with 20 m L matrine injection Based on this, all patients course of two weeks. The Karnofsky score and the expression of miR-125 in two groups before and after treatment were compared. The clinical curative effect and adverse reactions in two groups were observed. Results After treatment, the total effective rate (86.84%) in the test group was significantly higher than that in the control group (60.53%) (P <0.05). The Karnofsky score of the test group (83.23 ± 14.35) was also significantly higher than that of the control group (77.22 ± 11.31) (P <0.05). The expression of miR-125b in the experimental group (5.02 ± 0.75) was significantly lower than that in the control group (11.42 ± 1.44) (P <0.05). The incidence of Ⅲ-Ⅳ leukopenia (2.63%), erythrocyte reduction (2.63%), thrombocytopenia (0), liver injury (2.63%), oral mucositis and gastrointestinal serious adverse reactions Rates were significantly lower than the control group (P <0.05). Conclusion Matrine injection combined with chemotherapy can reduce the expression of miR-125b in patients with acute myeloid leukemia.